Tolerance to Chronic Delta-9-Tetrahydrocannabinol (Δ9-THC) in Rhesus Macaques Infected With Simian Immunodeficiency Virus

Experimental and Clinical Psychopharmacology

Volumn 19, Issue 2, 2011, Pages 154-172

  Winsauer, Peter J ^a   Molina, Patricia E ^b   Amedee, Angela M ^b   Filipeanu, Catalin M ^b   McGoey, Robin R ^b   Troxclair, Dana A ^b   Walker, Edith M ^b   Birke, Leslie L ^b   Stouwe, Curtis Vande ^b   Howard, Jessica M ^b   Leonard, Stuart T ^b   Moerschbaecher, Joseph M ^b   Lewis, Peter B ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Delta 9 tetrahydrocannabinol; Operant behavior; Rhesus monkey; Simian immunodeficiency virus; Tolerance

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG TOLERANCE; HIPPOCAMPUS; HISTOPATHOLOGY; MALE; NONHUMAN; OPPORTUNISTIC INFECTION; PLASMA; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; TREATMENT DURATION; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; DRUG TOLERANCE; MACACA MULATTA; POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TETRAHYDROCANNABINOL;

EID: 79954494851     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0023000     Document Type: Article

References (97)

1. Bagby G.J., Zhang P., Purcell J.E., Didier P.J., Nelson S. Chronic binge ethanol consumption accelerates progression of simian immunodeficiency virus disease. Alcoholism: Clinical and Experimental Research 2006, 30:1781-1790.
2. Beal J.E., Olson R., Laubenstein L., Morales J.O., Bellman P., Yangco B., Shepard K.V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management 1995, 10:89-97.
3. Beal J.E., Olson R., Lefkowitz L., Laubenstein L., Bellman P., Yangco B., Shepard K.V. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain Symptom Management 1997, 14:7-14.
4. Beardsley P.M., Balster R.L., Harris L.S. Behavioral dependence in rhesus monkeys following chronic THC administration. NIDA Research Monograph 1984, 55:111-117.
5. Benito C., Kim W.K., Chavarria I., Hillard C.J., Mackie K., Tolon R.M., Romero J. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. The Journal of Neuroscience 2005, 25:2530-2536.
6. Bickel W.K., Hughes J.R., Higgins S.T. Effects of delta-9-THC on repeated acquisition and performance of response chains in humans. NIDA Research Monograph 1989, 95:440-441.
7. Boren J.J. Repeated acquisition of new behavioral chains. American Psychologist 1963, 18:421.
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
9. Branch M.N., Dearing M.E., Lee D.M. Acute and chronic effects of delta 9-tetrahydrocannabinol on complex behavior of squirrel monkeys. Psychopharmacology (Berl) 1980, 71:247-256.
10. Bredt B.M., Higuera-Alhino D., Shade S.B., Hebert S.J., McCune J.M., Abrams D.I. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. The Journal of Clinical Pharmacology 2002, 42:82S-89S.
11. Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Vogt L.J., Sim-Selley L.J. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. Journal of Neurochemistry 1999, 73:2447-2459.
12. Brodkin J., Moerschbaecher J.M. SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. The Journal of Pharmacology and Experimental Therapeutics 1997, 282:1526-1532.
13. Cabral G.A., Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Reviews in Molecular Medicine 2009, 11:e3.
14. Carlini E.A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon 2004, 44:461-467.
15. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. International Immunopharmacology 2002, 2:69-82.
16. Cheney P.D., Riazi M., Marcario J.M. Behavioral and neurophysiological hallmarks of simian immunodeficiency virus infection in macaque monkeys. Journal of Neurovirology 2008, 14:301-308.
17. Chin C.L., Tovcimak A.E., Hradil V.P., Seifert T.R., Hollingsworth P.R., Chandran P., Fox G.B. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. British Journal of Pharmacology 2008, 153:367-379.
18. Cohn J., Cory-Slechta D.A. Subsensitivity of lead-exposed rats to the accuracy-impairing and rate-altering effects of MK-801 on a multiple schedule of repeated learning and performance. Brain Research 1993, 600:208-218.
19. Cohn J., Cox C., Cory-Slechta D.A. The effects of lead exposure on learning in a multiple repeated acquisition and performance schedule. Neurotoxicology 1993, 14:329-346.
20. Cohn J., Ziriax J.M., Cox C., Cory-Slechta D.A. Comparison of error patterns produced by scopolamine and MK-801 on repeated acquisition and transition baselines. Psychopharmacology (Berl) 1992, 107:243-254.
21. Coutts A.A., Anavi-Goffer S., Ross R.A., MacEwan D.J., Mackie K., Pertwee R.G., Irving A.J. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. The Journal of Neuroscience 2001, 21:2425-2433.
22. Cristiani S.A., Pukay-Martin N.D., Bornstein R.A. Marijuana use and cognitive function in HIV-infected people. Journal of Neuropsychiatry and Clinical Neurosciences 2004, 16:330-335.
23. da Cunha A., Eiden L.E., Rausch D.M. Neuronal substrates for SIV encephalopathy. Advances in Neuroimmunology 1994, 4:265-271.
24. Delatte M.S., Winsauer P.J., Moerschbaecher J.M. Tolerance to the disruptive effects of Delta(9)-THC on learning in rats. Pharmacology Biochemistry and Behavior 2002, 74:129-140.
25. Elsmore T.F. Effects of delta-9-tetrahydrocannabinol on temporal and auditory discrimination performances of monkeys. Psychopharmacologia 1972, 26:62-72.
26. Evans E.B., Wenger G.R. Effects of drugs of abuse on acquisition of behavioral chains in squirrel monkeys. Psychopharmacology (Berl) 1992, 107:55-60.
27. Ferraro D.P. Behavioral tolerance to marihuana. Behavioral tolerance: Research and treatment implications 1978, 103-117. U.S. Government Printing Office, Washington, DC. N. Krasnegor (Ed.).
28. Ferraro D.P., Grisham M.G. Tolerance to the behavioral effects of marihuana in chimpanzees. Physiology and Behavior 1972, 9:49-54.
29. Filipeanu C.M., Zhou F., Claycomb W.C., Wu G. Regulation of the cell surface expression and function of angiotensin II type 1 receptor by Rab1-mediated endoplasmic reticulum-to-Golgi transport in cardiac myocytes. The Journal of Biological Chemistry 2004, 279:41077-41084.
30. Fox H.S., Gold L.H., Henriksen S.J., Bloom F.E. Simian immunodeficiency virus: A model for neuroAIDS. Neurobiology of Disease 1997, 4:265-274.
31. Gold L.H., Fox H.S., Henriksen S.J., Buchmeier M.J., Weed M.R., Taffe M.A., Bloom F.E. Longitudinal analysis of behavioral, neurophysiological, viral and immunological effects of SIV infection in rhesus monkeys. Journal of Medical Primatology 1998, 27:104-112.
32. Goldstein R.Z., Tomasi D., Rajaram S., Cottone L.A., Zhang L., Maloney T., Volkow N.D. Role of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction. Neuroscience 2007, 144:1153-1159.
33. Gonzalez S., Cebeira M., Fernandez-Ruiz J. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacoloy Biochemistry and Behavior 2005, 81:300-318.
34. Gorter R., Seefried M., Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS 1992, 6:127.
35. Grant I., Heaton R.K., Atkinson J.H. Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center. Current Topics in Microbiology and Immunology 1995, 202:11-32.
36. Green J.E., Saveanu R.V., Bornstein R.A. The effect of previous alcohol abuse on cognitive function in HIV infection. The American Journal of Psychiatry 2004, 161:249-254.
37. Gruber S.A., Yurgelun-Todd D.A. Neuropsychological correlates of drug abuse. Brain imaging in substance abuse 2001, 199-229. Humana Press, Totowa, NJ. M.J. Kaufman (Ed.).
38. Hampson R.E., Deadwyler S.A. Cannabinoids, hippocampal function and memory. Life Sciences 1999, 65:715-723.
39. Hampson R.E., Deadwyler S.A. Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. The Journal of Neuroscience 2000, 20:8932-8942.
40. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. The Journal of Neuroscience 1991, 11:563-583.
41. Heyes M.P., Jordan E.K., Lee K., Saito K., Frank J.A., Snoy P.J., Gravell M. Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid. Brain Research 1992, 570:237-250.
42. Horn T.F., Huitron-Resendiz S., Weed M.R., Henriksen S.J., Fox H.S. Early physiological abnormalities after simian immunodeficiency virus infection. Proceedings of the National Academy of Sciences, USA 1998, 95:15072-15077.
43. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002, 54:161-202.
44. Hunault C.C., Mensinga T.T., Bocker K.B., Schipper C.M., Kruidenier M., Leenders M.E., Meulenbelt J. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) 2009, 204:85-94.
45. Jones R.T., Benowitz N., Bachman J. Clinical studies of cannabis tolerance and dependence. Annals of the New York Academy of Sciences 1976, 282:221-239.
46. Kamien J.B., Bickel W.K., Higgins S.T., Hughes J.R. The effects of delta(9)-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans. Behavioural Pharmacology 1994, 5:71-78.
47. Klatt E.C., Nichols L., Noguchi T.T. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982-1993 [corrected]. Archives of Pathology & Laboratory Medicine 1994, 118:884-890.
48. Klein T.W., Friedman H., Specter S. Marijuana, immunity and infection. Journal of Neuroimmunology 1998, 83:102-115.
49. Lamb R.J., Jarbe T.U., Makriyannis A., Lin S., Goutopoulos A. Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716, and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing. European Journal of Pharmacology 2000, 398:251-258.
50. Landfield P.W., Cadwallader L.B., Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: Possible mediation by glucocorticoid systems. Brain Research 1988, 443:47-62.
51. Liang H., Wang X., Chen H., Song L., Ye L., Wang S.H., Ho W.Z. Methamphetamine enhances HIV infection of macrophages. American Journal of Pathology 2008, 172:1617-1624.
52. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 1995, 119:282-290.
53. Marcario J.K., Raymond L.A., McKiernan B.J., Foresman L.L., Joag S.V., Raghavan R., Cheney P.D. Motor skill impairment in SIV-infected rhesus macaques with rapidly and slowly progressing disease. Journal of Medical Primatology 1999, 28:105-117.
54. McMillan D.E. Failure of acute and chronic administration of delta 9-tetrahydrocannabinol to affect the repeated acquisition of serial position response in pigeons. The Pavlovian Journal of Biological Science 1988, 23:57-66.
55. McMillan D.E., Hardwick W.C., Wells J.D. Effects of barbiturates in rats tolerant to delta 9-tetrahydrocannabinol. Archives Internationales de Pharmacodynamie et de Therapie 1983, 264:4-14.
56. Molina, P. E., Winsauer, P., Zhang, P., Walker, E., Birke, L., Amedee, A., LaMotte, L. (2010). Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Research and Human Retroviruses, 26, in press.
57. Murray E.A., Rausch D.M., Lendvay J., Sharer L.R., Eiden L.E. Cognitive and motor impairments associated with SIV infection in rhesus monkeys. Science 1992, March 6, 255:1246-1249.
58. Nakamura-Palacios E.M., Winsauer P.J., Moerschbaecher J.M. Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys. Behavioural Pharmacology 2000, 11:377-386.
59. Navia B.A., Jordan B.D., Price R.W. The AIDS dementia complex: I. Clinical features. Annals of Neurology 1986, 19:517-524.
60. Newman S.P., Lunn S., Harrison M.J. Do asymptomatic HIV-seropositive individuals show cognitive deficit?. AIDS 1995, 9:1211-1220.
61. Newton C.A., Klein T.W., Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infection and Immunity 1994, 62:4015-4020.
62. Noel R.J., Rivera-Amill V., Buch S., Kumar A. Opiates, immune system, acquired immunodeficiency syndrome, and nonhuman primate model. Journal of Neurovirology 2008, 14:279-285.
63. Oviedo A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. Brain Research 1993, 616:293-302.
64. Perdices M., Cooper D.A. Neuropsychological investigation of patients with AIDS and ARC. Journal of Acquired Immune Deficiency Syndromes 1990, 3:555-564.
65. Peterson P.K., Gekker G., Schut R., Hu S., Balfour H.H., Chao C.C. Enhancement of HIV-1 replication by opiates and cocaine: The cytokine connection. Advances in Experimental Medicine and Biology 1993, 335:181-188.
66. Peterson P.K., Gekker G., Hu S., Cabral G., Lokensgard J.R. Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. Journal of Neuroimmunology 2004, 147:123-126.
67. Poonia B., Nelson S., Bagby G.J., Zhang P., Quinton L., Veazey R.S. Chronic alcohol consumption results in higher simian immunodeficiency virus replication in mucosally inoculated rhesus macaques. AIDS Research and Human Retroviruses 2006, 22:589-594.
68. Power C., Johnson R.T. HIV-1 associated dementia: Clinical features and pathogenesis. The Canadian Journal of Neurological Sciences 1995, 22:92-100.
69. Prospero-Garcia O., Gold L.H., Fox H.S., Polis I., Koob G.F., Bloom F.E., Henriksen S.J. Microglia-passaged simian immunodeficiency virus induces neurophysiological abnormalities in monkeys. Proceedings of the National Academy of Science 1996, 93:14158-14163.
70. Rausch D.M., Heyes M.P., Murray E.A., Lendvay J., Sharer L.R., Ward J.M., Eiden L.E. Cytopathologic and neurochemical correlates of progression to motor/cognitive impairment in SIV-infected rhesus monkeys. Journal of Neuropathology & Experimental Neurology 1994, 53:165-175.
71. Rock R.B., Gekker G., Hu S., Sheng W.S., Cabral G.A., Martin B.R., Peterson P.K. WIN55, 212-2-mediated inhibition of HIV-1 expression in microglial cells: Involvement of cannabinoid receptors. Journal of Neuroimmune Pharmacology 2007, 2:178-183.
72. Rodriguez D.F., Gorriti M.A., Fernandez-Ruiz J.J., Palomo T., Ramos J.A. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacology Biochemistry and Behavior 1994, 47:33-40.
73. Romero J., Berrendero F., Manzanares J., Perez A., Corchero J., Fuentes J.A., Ramos J.A. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 1998, 30:298-308.
74. Rothlind J.C., Greenfield T.M., Bruce A.V., Meyerhoff D.J., Flenniken D.L., Lindgren J.A., Weiner M.W. Heavy alcohol consumption in individuals with HIV infection: Effects on neuropsychological performance. Journal of the International Neuropsychological Society 2005, 11:70-83.
75. Schulze G.E., McMillan D.E., Bailey J.R., Scallet A., Ali S.F., Slikker W., Paule M.G. Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests. The Journal of Pharmacology and Experimental Therapeutics 1988, 245:178-186.
76. Schuster C.R., Dockens W.S., Woods J.H. Behavioral variables affecting the development of amphetamine tolerance. Psychopharmacologia 1966, 9:170-182.
77. Selnes O.A., Galai N., Bacellar H., Miller E.N., Becker J.T., Wesch J., McArthur J.C. Cognitive performance after progression to AIDS: A longitudinal study from the Multicenter AIDS Cohort Study. Neurology 1995, 45:267-275.
78. Seman A.L., Pewen W.F., Fresh L.F., Martin L.N., Murphey-Corb M. The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. Journal of General Virology 2000, 81:2441-2449.
79. Silva de Melo L.C., Cruz A.P., Rios V.S., Marinho A.R., Mendonca J.B., Nakamura-Palacios E.M. Delta(9)-THC administered into the medial prefrontal cortex disrupts the spatial working memory. Psychopharmacology (Berl) 2005, 183:54-64.
80. Thompson D.M. Repeated acquisition of behavioral chains under chronic drug conditions. The Journal of Pharmacology and Experimental Therapeutics 1974, 188:700-713.
81. Thompson D.M., Moerschbaecher J.M. Operant methodology in the study of learning. Environmental Health Perspectives 1978, 26:77-87.
82. Thompson D.M., Moerschbaecher J.M. Drug effects on repeated acquisition. Advances in behavioral pharmacology 1979, 229-259. Academic Press, New York, NY. T. Thompson, P.B. Dews (Eds.).
83. Thompson D.M., Winsauer P.J., Mastropaolo J. Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacology Biochemistry and Behavior 1987, 26:401-405.
84. Vančata V., Vančatova M., Chalyan V.G., Meishvilli N. Longitudinal study of growth and body mass changes in ontogeny in captive rhesus macaques (Macaca mulatta) from the Institute of Medical Primatology, Sochi. Variability and Evolution 2000, 8:51-81.
85. Van Sickle M.D., Duncan M., Kingsley A.M., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
86. van Wagenen G., Catchpole H.R. Physical growth of the rhesus monkey (Macaca mulatta). American Journal of Physical Anthropology 1956, 14:245-273.
87. Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007, 145:323-334.
88. Weed M.R., Gold L.H., Polis I., Koob G.F., Fox H.S., Taffe M.A. Impaired performance on a rhesus monkey neuropsychological testing battery following simian immunodeficiency virus infection. AIDS Research and Human Retroviruses 2004, 20:77-89.
89. Whitfield R.M., Bechtel L.M., Starich G.H. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcoholism: Clinical and Experimental Research 1997, 21:122-127.
90. Wilson W.H., Ellinwood E.H., Mathew R.J., Johnson K. Effects of marijuana on performance of a computerized cognitive-neuromotor test battery. Psychiatry Research 1994, 51:115-125.
91. Winsauer P.J., Daniel J.M., Filipeanu C.M., Leonard S.T., Hulst J.L., Rodgers S.P., Sutton J.L. Long-term behavioral and pharmacodynamic effects of delta-9-tetrahydrocannabinol in female rats depend on ovarian hormone status. Addiction Biology 2011, 16:64-81.
92. Winsauer P.J., Delatte M.S., Stevenson M.W., Moerschbaecher J.M. Effects of triazolam, 8-OH-DPAT, and buspirone on repeated acquisition in squirrel monkeys. Experimental and Clinical Psychopharmacology 2002, 10:392-399.
93. Winsauer P.J., Lambert P., Moerschbaecher J.M. Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behavioural Pharmacology 1999, 10:497-511.
94. Winsauer P.J., Mele P.C. Effects of sublethal doses of ionizing radiation on repeated acquisition in rats. Pharmacology Biochemistry and Behavior 1993, 44:809-814.
95. Winsauer P.J., Moerschbaecher J.M., Brauner I.N., Purcell J.E., Lancaster J.R., Bagby G.J., Nelson S. Alcohol unmasks simian immunodeficiency virus-induced cognitive impairments in rhesus monkeys. Alcoholism: Clinical and Experimental Research 2002, 26:1846-1857.
96. Yao B.B., Hsieh G., Daza A.V., Fan Y., Grayson G.K., Garrison T.R., Meyer M.D. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. The Journal of Pharmacology and Experimental Therapeutics 2009, 328:141-151.
97. Zhu L.X., Sharma S., Stolina M., Gardner B., Roth M.D., Tashkin D.P., Dubinett S.M. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. The Journal of Immunology 2000, 165:373-380.